Literature DB >> 29991643

Influence of Clinical Factors and Exclusion Criteria on Mortality in ARDS Observational Studies and Randomized Controlled Trials.

Faye M Pais1, Pratik Sinha2, Kathleen D Liu3, Michael A Matthay4.   

Abstract

ARDS has a high mortality in the acute setting, with long-term disability among disease survivors. In 1967, David Ashbaugh and colleagues first described the clinical features of ARDS, which were notably similar to the infantile respiratory distress syndrome. Half a century later, ARDS remains underrecognized and is associated with high mortality rates. Valuable insights from observational studies fail to demonstrate a mortality benefit in randomized controlled trials (RCTs). In the absence of a pharmacologic cure, supportive ventilator strategies limit rather than treat the ongoing lung injury. Interestingly, ARDS has higher mortality rates in observational studies compared to RCTs. Comparing mortality rates between ARDS studies and trials is problematic, partly due to varying time-points at which mortality is reported. Discerning the true mortality attributable to ARDS is also difficult. The diagnostic criteria for ARDS are mainly clinical and lack the objectivity of a laboratory test or biomarker. Nonetheless, these factors are common to both studies and trials, and fail to explain the higher mortality rate of ARDS observational studies. Disease heterogeneity and complex patient characteristics can also confound mortality estimation in ARDS. We therefore examined patient and trial factors that could influence mortality outcomes in ARDS observational studies and RCTs. Unlike RCTs, observational studies include ARDS subjects with severe comorbidities and those requesting limited care. Less stringent selection criteria could thereby contribute to high mortality rates in ARDS observational studies. In contrast, exclusion criteria in RCTs meticulously scrutinize patient characteristics, confining the type and number of eligible subjects. As a result, the task of identifying, consenting, and randomizing eligible patients within the enrollment window is challenging, further decreasing the number of subjects enrolled. Moreover, ARDS RCTs strictly adhere to lung-protective strategies, while ARDS observational studies continually demonstrate variable compliance. This review highlights the impact of patient- and trial-related factors on influencing mortality rates in ARDS observational studies and RCTs.
Copyright © 2018 by Daedalus Enterprises.

Entities:  

Keywords:  ARDS; acute respiratory distress syndrome network; cancer; controlled trials; limitation of care; liver disease; mortality; observational studies; randomized

Mesh:

Year:  2018        PMID: 29991643     DOI: 10.4187/respcare.06034

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  9 in total

1.  Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis.

Authors:  Manoj V Maddali; Matthew Churpek; Tai Pham; Emanuele Rezoagli; Hanjing Zhuo; Wendi Zhao; June He; Kevin L Delucchi; Chunxue Wang; Nancy Wickersham; J Brennan McNeil; Alejandra Jauregui; Serena Ke; Kathryn Vessel; Antonio Gomez; Carolyn M Hendrickson; Kirsten N Kangelaris; Aartik Sarma; Aleksandra Leligdowicz; Kathleen D Liu; Michael A Matthay; Lorraine B Ware; John G Laffey; Giacomo Bellani; Carolyn S Calfee; Pratik Sinha
Journal:  Lancet Respir Med       Date:  2022-01-10       Impact factor: 102.642

2.  Presence of comorbidities alters management and worsens outcome of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study.

Authors:  Emanuele Rezoagli; Bairbre A McNicholas; Fabiana Madotto; Tài Pham; Giacomo Bellani; John G Laffey
Journal:  Ann Intensive Care       Date:  2022-05-21       Impact factor: 10.318

3.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Authors:  Michael A Matthay; Carolyn S Calfee; Hanjing Zhuo; B Taylor Thompson; Jennifer G Wilson; Joseph E Levitt; Angela J Rogers; Jeffrey E Gotts; Jeanine P Wiener-Kronish; Ednan K Bajwa; Michael P Donahoe; Bryan J McVerry; Luis A Ortiz; Matthew Exline; John W Christman; Jason Abbott; Kevin L Delucchi; Lizette Caballero; Melanie McMillan; David H McKenna; Kathleen D Liu
Journal:  Lancet Respir Med       Date:  2018-11-16       Impact factor: 30.700

4.  Physiologic Analysis and Clinical Performance of the Ventilatory Ratio in Acute Respiratory Distress Syndrome.

Authors:  Pratik Sinha; Carolyn S Calfee; Jeremy R Beitler; Neil Soni; Kelly Ho; Michael A Matthay; Richard H Kallet
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 30.528

5.  Methodological management of end-of-life decision data in intensive care studies: A systematic review of 178 randomized control trials published in seven major journals.

Authors:  Sébastien Kerever; Alice Jacquens; Violaine Smail-Faugeron; Etienne Gayat; Matthieu Resche-Rigon
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

6.  Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury.

Authors:  Yue Zhou; Pengfei Li; Andrew J Goodwin; James A Cook; Perry V Halushka; Eugene Chang; Basilia Zingarelli; Hongkuan Fan
Journal:  Crit Care       Date:  2019-02-13       Impact factor: 9.097

7.  Correlation analysis between mechanical power, transforming growth factor-β1, and connective tissue growth factor levels in acute respiratory distress syndrome patients and their clinical significance in pulmonary structural remodeling.

Authors:  Yongpeng Xie; Yangli Wang; Kexi Liu; Xiaomin Li
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

8.  Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study.

Authors:  Pratik Sinha; Kevin L Delucchi; Yue Chen; Hanjing Zhuo; Jason Abbott; Chunxue Wang; Nancy Wickersham; J Brennan McNeil; Alejandra Jauregui; Serena Ke; Kathryn Vessel; Antonio Gomez; Carolyn M Hendrickson; Kirsten N Kangelaris; Aartik Sarma; Aleksandra Leligdowicz; Kathleen D Liu; Michael A Matthay; Lorraine B Ware; Carolyn S Calfee
Journal:  Thorax       Date:  2021-07-12       Impact factor: 9.139

9.  Mechanical stretch and LPS affect the proliferation, extracellular matrix remodeling and viscoelasticity of lung fibroblasts.

Authors:  Yongpeng Xie; Ying Qian; Yanli Wang; Kexi Liu; Xiaomin Li
Journal:  Exp Ther Med       Date:  2020-08-25       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.